Trial reportNaunyn-Schmiedeberg's archives of pharmacology2026
Montelukast impressively mitigates biomarkers of inflammation in non-ST-segment elevation myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial.
Trial report in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myocardial infarction (AMI) is one of the most important components of cardiovascular disorders and the leading cause of worldwide morbidity and mortality. High-sensitivity C-reactive protein (hs-CRP) is a significant inflammatory predictor of AMI. This investigation aimed to assess the effects of the leukotriene receptor antagonist Montelukast on hs-CRP amounts in the context of patients suffering from non-ST-elevation myocardial infarction (NSTEMI). We selected 64 patients with NSTEMI for this double-blind, randomized controlled trial. Primary laboratory tests, including hs-CRP, CBC diff, lipid profile, and interleukin-6 (IL-6), were performed at baseline. The treatment group received 10 mg of Montelukast twice daily, and the placebo group received tablets similar in size and shape to Montelukast, taken twice daily, in addition to their usual protocol. Lipid profile, CBC diff, IL-6, and hs-CRP were reassessed after a 4-week course of treatment. Our findings emphasized that hs-CRP and IL-6 values were notably diminished in NSTEMI patients in both the Montelukast and placebo groups, related to baseline (P < 0.001). Interestingly, Montelukast robustly alleviated the hs-CRP and IL-6 amounts more than the placebo group following the 30-day treatment (P = 0.004 for both). A comparison between the two groups revealed that the mean changes in hs-CRP prior to and after treatment were statistically greater in the Montelukast group than in the placebo group (P = 0.002). The findings highlighted that Montelukast may mitigate inflammatory indicators, namely, hs-CRP and IL-6, and could be considered for NSTEMI patients. Otherwise, more clinical trials are required to determine its effectiveness in clinical administration.
Indexed as
Identifiers
41870545What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.